Search

Cogent Biosciences Inc

Fechado

32.34 3.03

Visão Geral

Variação de preço das ações

24h

Atual

Mín

32.18

Máximo

32.68

Indicadores-chave

By Trading Economics

Rendimento

947K

-96M

EPS

-0.52

Funcionários

258

EBITDA

537K

-94M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+72.29% upside

Dividendos

By Acuity

Próximos Ganhos

2 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.1B

5.6B

Abertura anterior

29.31

Fecho anterior

32.34

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de set. de 2026, 23:31 UTC

S&P Global Manufacturing PMI for South Korea set to release on October 1, 2026, amid cautious market expectations influenced by rising energy prices and geopolitical tensions.

26 de set. de 2026, 23:31 UTC

S&P/Case-Shiller Home Price Index Set for Release with Anticipated 2.2% Growth Amid Mixed Market Sentiment and Economic Pressures

26 de set. de 2026, 23:31 UTC

Brazil's Industrial Production MoM data release on October 2, 2026, expected to show growth trends amid recent fluctuations.

26 de set. de 2026, 23:22 UTC

U.S. Q2 GDP Growth Rate Forecasted at +1.6% Amid Economic Concerns and Market Volatility Ahead of September 30 Release

26 de set. de 2026, 23:22 UTC

Upcoming PCE Price Index release on September 30 raises inflation concerns amid rising commodity prices and geopolitical tensions.

26 de set. de 2026, 23:22 UTC

U.S. Personal Spending Expected to Rise 0.8% in August Amid Caution Over Inflation and Consumer Confidence Decline

26 de set. de 2026, 23:22 UTC

Upcoming U.S. Retail Inventories Ex Autos Report on September 30 Expected to Reflect Consumer Demand Amid Mixed Economic Signals.

26 de set. de 2026, 23:22 UTC

U.S. Goods Trade Balance Report Set for Release Amid Anticipated $108.5 Billion Deficit and Positive Tariff Negotiations with China

26 de set. de 2026, 23:22 UTC

US Personal Income Expected to Rise 0.4% in August Amid Economic Recovery and Inflation Concerns

26 de set. de 2026, 23:22 UTC

U.S. Wholesale Inventories Expected to Rise 1.1% Amid Mixed Investor Sentiment and Inflation Concerns Ahead of September Release

26 de set. de 2026, 23:22 UTC

U.S. GDP Price Index Expected to Rise 0.064% Amid Mixed Economic Sentiment and Inflation Concerns Ahead of September Release

26 de set. de 2026, 23:22 UTC

Core PCE Price Index MoM for August 2026 set to release on September 30, with a forecasted increase of 0.3%, amid cautious investor sentiment and rising treasury yields impacting Fed policy outlook.

26 de set. de 2026, 23:22 UTC

U.S. PCE Price Index Release on September 30 Expected to Show 0.4% Monthly Increase Amid Inflation Concerns and Market Volatility

26 de set. de 2026, 23:11 UTC

Cautious Market Anticipates 70,000 Job Increase in Upcoming ADP Employment Report Amid Recent Underperformance

26 de set. de 2026, 23:11 UTC

Mexican Business Confidence Remains Cautious Ahead of October EMOE Release Amid U.S. Economic Concerns

26 de set. de 2026, 23:11 UTC

Correlated Moves

Avalanche is trading higher, continuing its upward trend since Friday, while Ethereum remains little changed amid broader market support from easing oil prices and Treasury yields.

26 de set. de 2026, 23:01 UTC

Canada's Preliminary Monthly GDP Release on September 29 Expected to Show Stability Amid Economic Challenges and Trade Tensions.

26 de set. de 2026, 23:01 UTC

South Korea's October 1 export report expected to show continued strong growth, following August's impressive 68.7% surge driven by memory chip demand.

26 de set. de 2026, 22:51 UTC

Japan's unemployment rate forecasted to drop slightly to 2.4% in August, amid cautious market optimism and concerns over currency depreciation and rising interest rates ahead of the October release.

26 de set. de 2026, 22:51 UTC

South Africa's Balance of Trade report on September 30, 2026, expected to show continued trade surplus amid cautious optimism in exports and declining imports.

26 de set. de 2026, 22:51 UTC

Germany's Inflation Rate Release on September 30, 2026: Consumer Confidence Declines Amid Rising Energy Prices and Economic Uncertainty.

26 de set. de 2026, 22:51 UTC

Japan's Tankan Index Set for Positive Release Amid Cautious Market Optimism and Global Economic Pressures

26 de set. de 2026, 22:51 UTC

Germany's Inflation Rate Expected to Rise 0.5% Amid Declining Consumer Confidence Due to Soaring Energy Prices

26 de set. de 2026, 22:51 UTC

Macro News

The Russell 2000 Index is trading lower in after-hours, reflecting a slight decline since Friday's close, amid rising delinquency rates in the commercial real estate sector.

26 de set. de 2026, 22:51 UTC

Macro News

The Dow Jones Index is lower in after-market trading, amid trade tariff discussions and rising delinquency rates in commercial real estate.

26 de set. de 2026, 22:51 UTC

Macro News

The FTSE 100 Index has advanced modestly in after-market hours, following a U.S.-China tariff agreement on $30 billion in goods.

26 de set. de 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Hits 7.12%, Highest Since May, Amid Rising Treasury Yields and Inflation Concerns

26 de set. de 2026, 22:40 UTC

Macro News

The DAX 30 Index is trading modestly lower in after-market hours, continuing its downward trend amid ongoing macroeconomic concerns and trade developments.

26 de set. de 2026, 22:31 UTC

Japan's Industrial Production Expected to Rise 1.7% in August Amidst Cautious Optimism and Global Uncertainties

26 de set. de 2026, 22:31 UTC

Japan's Retail Sales YoY data for August expected to rise 3.3% amid cautious optimism and inflation concerns, with market focus on currency valuation and global trends.

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

72.29% parte superior

Previsão para 12 meses

Média 55.667 USD  72.29%

Máximo 62 USD

Mínimo 52 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

6

Comprar

1

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.